fbpx
logo
Services Testimonials Resources About Refill Request Contact
Free Consult
Articles

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies

By Endogenous Hormones and Prostate Cancer Collaborative Group

Abstract

Background

Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. We performed a collaborative analysis of the existing worldwide epidemiologic data to examine these associations in a uniform manner and to provide more precise estimates of risks.

Methods

Data on serum concentrations of sex hormones from 18 prospective studies that included 3886 men with incident prostate cancer and 6438 control subjects were pooled by the Endogenous Hormones and Prostate Cancer Collaborative Group. Relative risks (RRs) of prostate cancer by fifths of serum hormone concentration were estimated by use of conditional logistic regression with stratification by study, age at recruitment, and year of recruitment. All statistical tests were two-sided.

Results

No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol. The serum concentration of sex hormone–binding globulin was modestly inversely associated with prostate cancer risk (RR in the highest vs lowest fifth = 0.86, 95% confidence interval = 0.75 to 0.98; Ptrend = .01). There was no statistical evidence of heterogeneity among studies, and adjustment for potential confounders made little difference to the risk estimates.

Conclusions

In this collaborative analysis of the worldwide data on endogenous hormones and prostate cancer risk, serum concentrations of sex hormones were not associated with the risk of prostate cancer.

References

  • 1.Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Version 2.0. Lyon, France: IARC Press; 2004. [Google Scholar]
  • 2.Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371–2490. doi: 10.1002/cncr.20408. [DOI] [PubMed] [Google Scholar]
  • 3.Hsing AW. Hormones and prostate cancer: what’s next? Epidemiol Rev. 2001;23:42–58. doi: 10.1093/oxfordjournals.epirev.a000795. [DOI] [PubMed] [Google Scholar]
  • 4.Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:237–253. doi: 10.1016/j.jsbmb.2004.10.002. [DOI] [PubMed] [Google Scholar]
  • 5.Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224. doi: 10.1056/NEJMoa030660. [DOI] [PubMed] [Google Scholar]
  • 6.Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol. 2007;51:27–33. doi: 10.1016/j.eururo.2006.09.002. [DOI] [PubMed] [Google Scholar]
  • 7.Nomura AMY, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate-cancer. Cancer Res. 1988;48:3515–3517. [PubMed] [Google Scholar]
  • 8.Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic-cancer. Cancer Res. 1990;50:169–173. [PubMed] [Google Scholar]
  • 9.Hsing AW, Comstock GW. Serological precursors of cancer—serum hormones and risk of subsequent prostate-cancer. Cancer Epidemiol Biomarkers Prev. 1993;2:27–32. [PubMed] [Google Scholar]
  • 10.Comstock GW, Gordon GB, Hsing AW. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev. 1993;2:219–221. [PubMed] [Google Scholar]
  • 11.Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate-cancer. Prostate. 1995;27:25–31. doi: 10.1002/pros.2990270106. [DOI] [PubMed] [Google Scholar]
  • 12.Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal-variation in vitamin-D, vitamin-D-binding protein, and dehydroepiandrosterone—risk of prostate-cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995;4:655–659. [PubMed] [Google Scholar]
  • 13.Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–1126. doi: 10.1093/jnci/88.16.1118. [DOI] [PubMed] [Google Scholar]
  • 14.Nomura AMY, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:621–625. [PubMed] [Google Scholar]
  • 15.Guess HA, Friedman GD, Sadler MC, et al. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev. 1997;6:21–24. [PubMed] [Google Scholar]
  • 16.Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6:967–969. [PubMed] [Google Scholar]
  • 17.Dorgan JP, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7:1069–1074. [PubMed] [Google Scholar]
  • 18.Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma—a longitudinal study. Cancer. 1999;86:312–315. [PubMed] [Google Scholar]
  • 19.Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57:930–935. doi: 10.1016/s0090-4295(00)01116-x. [DOI] [PubMed] [Google Scholar]
  • 20.Stattin P, Rinaldi S, Stenman UH, et al. Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer. 2001;92:463–465. doi: 10.1002/ijc.1191. [DOI] [PubMed] [Google Scholar]
  • 21.Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev. 2003;12:1410–1416. [PubMed] [Google Scholar]
  • 22.Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108:418–424. doi: 10.1002/ijc.11572. [DOI] [PubMed] [Google Scholar]
  • 23.Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004;95:65–71. doi: 10.1111/j.1349-7006.2004.tb03172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14:2257–2260. doi: 10.1158/1055-9965.EPI-04-0715. [DOI] [PubMed] [Google Scholar]
  • 25.Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262–1269. doi: 10.1158/1055-9965.EPI-04-0371. [DOI] [PubMed] [Google Scholar]
  • 26.Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:86–91. doi: 10.1158/1055-9965.EPI-05-0633. [DOI] [PubMed] [Google Scholar]
  • 27.Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121:1331–1338. doi: 10.1002/ijc.22814. [DOI] [PubMed] [Google Scholar]
  • 28.Oliver SE, Gunnell D, Donovan J, et al. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer. 2004;108:887–892. doi: 10.1002/ijc.11631. [DOI] [PubMed] [Google Scholar]
  • 29.Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801–810. doi: 10.1016/0022-4731(82)90038-3. [DOI] [PubMed] [Google Scholar]
  • 30.Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672. doi: 10.1210/jcem.84.10.6079. [DOI] [PubMed] [Google Scholar]
  • 31.Rinaldi S, Geay A, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11:1065–1071. [PubMed] [Google Scholar]
  • 32.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. doi: 10.1002/sim.1186. [DOI] [PubMed] [Google Scholar]
  • 33.Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 2000;3:157–172. doi: 10.1038/sj.pcan.4500421. [DOI] [PubMed] [Google Scholar]
  • 34.Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999;80:930–934. doi: 10.1038/sj.bjc.6690445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000;18:847–853. doi: 10.1200/JCO.2000.18.4.847. [DOI] [PubMed] [Google Scholar]
  • 36.Bosland MC. Chapter 2: the role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000;(27):39–66. doi: 10.1093/oxfordjournals.jncimonographs.a024244. [DOI] [PubMed] [Google Scholar]
  • 37.Hsing AW. Hormones and prostate cancer: where do we go from here? J Natl Cancer Inst. 1996;88:1093–1095. doi: 10.1093/jnci/88.16.1093. [DOI] [PubMed] [Google Scholar]
  • 38.Russell DW, Wilson JD. Steroid 5-α-reductase—2 genes 2 enzymes. Annu Rev Biochem. 1994;63:25–61. doi: 10.1146/annurev.bi.63.070194.000325. [DOI] [PubMed] [Google Scholar]
  • 39.Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993;150:1736–1739. doi: 10.1016/s0022-5347(17)35882-2. [DOI] [PubMed] [Google Scholar]
  • 40.Stanczyk FZ, Skinner EC, Mertes S, Spahn MF, Lobo RA, Ross RK. Alterations in circulating levels of androgens and PSA during treatment with finasteride in men at high risk of prostate cancer. In: Li JJ, Li SA, Gustafsson J, Nandi S, Sekely LI, editors. Hormonal Carcinogenesis II. New York: Springer; 1996. pp. 404–407. [Google Scholar]
  • 41.Rittmaster RS, Thompson DL, Listwak S, Loriaux DL. Androstanediol glucuronide isomers in normal men and women and in men infused with labeled dihydrotestosterone. J Clin Endocrinol Metab. 1988;66:212–216. doi: 10.1210/jcem-66-1-212. [DOI] [PubMed] [Google Scholar]
  • 42.Thompson DL, Rittmaster RS, Rodriguez AM, Moore PHJ, Rao PN. Synthesis of new steroid haptens for radioimmunoassay—VIII. Development and validation of a specific radioimmunoassay for serum 5 alpha-androstane-3 alpha, 17 beta-diol 17-glucuronide. J Steroid Biochem. 1990;36:345–349. doi: 10.1016/0022-4731(90)90227-j. [DOI] [PubMed] [Google Scholar]
  • 43.Rao PN, Burdett JEJ, Moore PHJ, Horton R. Isolation and identification of androstanediol glucuronide from human plasma. J Steroid Biochem. 1987;28:565–569. doi: 10.1016/0022-4731(87)90516-4. [DOI] [PubMed] [Google Scholar]
  • 44.Tiitinen A, Simberg N, Stenman UH, Ylikorkala O. Estrogen replacement does not potentiate gonadotropin-releaseing hormone agonist-induced androgen suppression in treatment of hirsutism. J Clin Endocrinol Metab. 1994;79:447–451. doi: 10.1210/jcem.79.2.8045961. [DOI] [PubMed] [Google Scholar]
  • 45.Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024. doi: 10.1093/jnci/91.12.1017. [DOI] [PubMed] [Google Scholar]
  • 46.Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem. 2004;91:553–571. doi: 10.1002/jcb.10700. [DOI] [PubMed] [Google Scholar]
  • 47.Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–878. doi: 10.1093/jnci/95.12.868. [DOI] [PubMed] [Google Scholar]
  • 48.Stenman UH, Leinonen J, Hakama M, Knekt P, Aromaa A, Teppo L. Serum concentrations of prostate specific antigen and its complex with [α]1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594–1598. doi: 10.1016/s0140-6736(94)90405-7. [DOI] [PubMed] [Google Scholar]
  • 49.Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in 7 areas—collaborative study organized by International Agency For Research On Cancer, Lyons, France. Int J Cancer. 1977;20:680–688. doi: 10.1002/ijc.2910200506. [DOI] [PubMed] [Google Scholar]
  • 50.McShane LM, Midthune DN, Dorgan JF, Freedman LS, Carroll RJ. Covariate measurement error adjustment for matched case-control studies. Biometrics. 2001;57:62–73. doi: 10.1111/j.0006-341x.2001.00062.x. [DOI] [PubMed] [Google Scholar]
  • 51.Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long-term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939–942. doi: 10.1210/jcem.74.4.1548361. [DOI] [PubMed] [Google Scholar]
  • 52.Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson BE. Serum testosterone levels in healthy-young black-and-white men. J Natl Cancer Inst. 1986;76:45–48. [PubMed] [Google Scholar]
  • 53.Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero estrogen and testosterone environment of blacks and whites—potential effects on male offspring. Br J Cancer. 1988;57:216–218. doi: 10.1038/bjc.1988.46. [DOI] [PMC free article] [PubMed] [Google Scholar]


Read the Full Article
All